TY  - JOUR
AU  - Schumann, Katharina
AU  - Klespe, Kai Christian
AU  - Mauch, Cornelia
AU  - Loquai, Carmen
AU  - Schultheis, Ulrike
AU  - Börger, Sevil
AU  - Thiem, Alexander
AU  - Emmert, Steffen
AU  - Hoellwerth, Magdalena
AU  - Koelbinger, Peter
AU  - Nguyen, Van Anh
AU  - Wanner, Marina
AU  - Richtig, Erika
AU  - Peitsch, Wiebke K
AU  - Harth, Wolfgang
AU  - Zenderowski, Veronika
AU  - Braun, Andreas Dominik
AU  - Mengoni, Miriam
AU  - Dummer, Reinhard
AU  - Mangana, Johanna
AU  - Maul, Lara Valeska
AU  - Meis, Frank
AU  - Rappersberger, Klemens
AU  - Persa, Oana Diana
AU  - Biedermann, Tilo
AU  - Posch, Christian
TI  - Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.
JO  - Journal of the European Academy of Dermatology and Venereology
VL  - nn
SN  - 0926-9959
CY  - Oxford [u.a.]
PB  - Wiley-Blackwell
M1  - DKFZ-2025-00939
SP  - nn
PY  - 2025
N1  - epub
AB  - PD-1 or BRAF + MEK inhibition is considered the current gold standard in adjuvant melanoma therapy. Little is known if, after the recurrence of the disease and surgery, a second course of adjuvant therapy might be beneficial.A multicenter, retrospective study investigating a second course of adjuvant therapy after recurrence and surgery in stage III-IV melanoma patients. Patients received nivolumab (NIV), pembrolizumab (PEM) or dabrafenib plus trametinib (D + T) between 01/2017 and 10/2021. The primary endpoint was 12-month recurrence-free survival (RFS2). Further analyses included descriptive and correlative statistics.Sixty-six patients from 22 centers in Germany, Austria and Switzerland were included. Thirty-two patients received D + T as second-course adjuvant therapy, 9 patients received PEM and 25 patients received NIV. Recurrence-free survival for the second-course adjuvant treatment (RFS2) was assessed after 12 and 24 months and showed a superiority of adjuvant BRAF + MEK over PD-1 therapy (12-months RFS2: 90.6
LB  - PUB:(DE-HGF)16
C6  - pmid:40331873
DO  - DOI:10.1111/jdv.20708
UR  - https://inrepo02.dkfz.de/record/300825
ER  -